BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9392560)

  • 1. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
    Roberts SA; Hendry JH; Slevin NJ
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time factors in larynx tumor radiotherapy: lag times and intertumor heterogeneity in clinical datasets from four centers.
    Roberts SA; Hendry JH
    Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1247-57. PubMed ID: 10613320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy.
    Slevin NJ; Hendry JH; Roberts SA; Agren-Cronqvist A
    Radiother Oncol; 1992 Aug; 24(4):215-20. PubMed ID: 1410576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum overall times II: Extended modelling for head and neck radiotherapy.
    Fowler JF
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):113-26. PubMed ID: 18155893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.
    Robertson AG; Robertson C; Boyle P; Symonds RP; Wheldon TE
    Eur J Cancer; 1993; 29A(4):501-10. PubMed ID: 8435200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why to start the concomitant boost in accelerated radiotherapy for advanced laryngeal cancer in week 3.
    Terhaard CH; Kal HB; Hordijk GJ
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):62-9. PubMed ID: 15850903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivation of the optimum dose per fraction from the linear quadratic model.
    Jones B; Tan LT; Dale RG
    Br J Radiol; 1995 Aug; 68(812):894-902. PubMed ID: 7551788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity.
    Roberts SA; Hendry JH
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):689-99. PubMed ID: 9635721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling.
    Fowler JF
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):8-22. PubMed ID: 17305251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further analysis of radiobiological parameters from the First and Second British Institute of Radiology randomized studies of larynx/pharynx radiotherapy.
    Chappell R; Nondahl DM; Rezvani M; Fowler JF
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):509-18. PubMed ID: 7673041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of treatment time and smoking on local control and complications in T1 glottic cancer.
    van der Voet JC; Keus RB; Hart AA; Hilgers FJ; Bartelink H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):247-55. PubMed ID: 9788401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations.
    Fowler JF
    Radiother Oncol; 1990 Jun; 18(2):165-81. PubMed ID: 2367691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.
    van Leeuwen CM; Oei AL; Crezee J; Bel A; Franken NAP; Stalpers LJA; Kok HP
    Radiat Oncol; 2018 May; 13(1):96. PubMed ID: 29769103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional fractionation should not be the standard of care for T2 glottic cancer.
    Dixon LM; Douglas CM; Shaukat SI; Garcez K; Lee LW; Sykes AJ; Thomson D; Slevin NJ
    Radiat Oncol; 2017 Nov; 12(1):178. PubMed ID: 29137654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What hypofractionated protocols should be tested for prostate cancer?
    Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules.
    Garden AS; Morrison WH; Ang KK; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):493-502. PubMed ID: 7852111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor.
    Roberts SA; Hendry JH; Brewster AE; Slevin NJ
    Br J Radiol; 1994 Aug; 67(800):790-4. PubMed ID: 8087485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx.
    Krstevska V; Crvenkova S
    Croat Med J; 2006 Feb; 47(1):42-52. PubMed ID: 16489696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of tumor repopulation on radiotherapy planning.
    Wang JZ; Li XA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated radiotherapy for T1 to T2 glottic cancer.
    Motegi A; Kawashima M; Arahira S; Zenda S; Toshima M; Onozawa M; Hayashi R; Akimoto T
    Head Neck; 2015 Apr; 37(4):579-84. PubMed ID: 24677592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.